Global α1 Adrenergic Agonist Market Size, Status and Forecast 2019-2025

Table of Contents

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered
• 1.4 Market Analysis by Type
  • 1.4.1 Global α1 Adrenergic Agonist Market Size Growth Rate by Type (2014-2025)
  • 1.4.2 Phenylephrine
  • 1.4.3 Methoxamine
  • 1.4.4 Midodrine
  • 1.4.5 Oxymetazoline
• 1.5 Market by Application
  • 1.5.1 Global α1 Adrenergic Agonist Market Share by Application (2014-2025)
  • 1.5.2 Paroxysmal Supraventricular Tachycardia
  • 1.5.3 Eye Drops
  • 1.5.4 Anaphylaxis
  • 1.5.5 Cardiac Arrest
  • 1.5.6 Anaphylaxis
  • 1.5.7 Cardiac Arrest
  • 1.5.8 Others
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 α1 Adrenergic Agonist Market Size
• 2.2 α1 Adrenergic Agonist Growth Trends by Regions
  • 2.2.1 α1 Adrenergic Agonist Market Size by Regions (2014-2025)
  • 2.2.2 α1 Adrenergic Agonist Market Share by Regions (2014-2019)
• 2.3 Industry Trends
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players

• 3.1 α1 Adrenergic Agonist Market Size by by Players
  • 3.1.1 Global α1 Adrenergic Agonist Revenue by by Players (2014-2019)
  • 3.1.2 Global α1 Adrenergic Agonist Revenue Market Share by by Players (2014-2019)
  • 3.1.3 Global α1 Adrenergic Agonist Market Concentration Ratio (CR5 and HHI)
• 3.2 α1 Adrenergic Agonist Key Players Head office and Area Served
• 3.3 Key Players α1 Adrenergic Agonist Product/Solution/Service
• 3.4 Date of Enter into α1 Adrenergic Agonist Market
• 3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

• 4.1 Global α1 Adrenergic Agonist Market Size by Type (2014-2019)
• 4.2 Global α1 Adrenergic Agonist Market Size by Application (2014-2019)

5 United States

• 5.1 United States α1 Adrenergic Agonist Market Size (2014-2019)
• 5.2 α1 Adrenergic Agonist Key Players in United States
• 5.3 United States α1 Adrenergic Agonist Market Size by Type
• 5.4 United States α1 Adrenergic Agonist Market Size by Application

6 Europe

• 6.1 Europe α1 Adrenergic Agonist Market Size (2014-2019)
• 6.2 α1 Adrenergic Agonist Key Players in Europe
• 6.3 Europe α1 Adrenergic Agonist Market Size by Type
• 6.4 Europe α1 Adrenergic Agonist Market Size by Application

7 China

• 7.1 China α1 Adrenergic Agonist Market Size (2014-2019)
• 7.2 α1 Adrenergic Agonist Key Players in China
• 7.3 China α1 Adrenergic Agonist Market Size by Type
• 7.4 China α1 Adrenergic Agonist Market Size by Application

8 Japan

• 8.1 Japan α1 Adrenergic Agonist Market Size (2014-2019)
• 8.2 α1 Adrenergic Agonist Key Players in Japan
• 8.3 Japan α1 Adrenergic Agonist Market Size by Type
• 8.4 Japan α1 Adrenergic Agonist Market Size by Application

9 Southeast Asia

• 9.1 Southeast Asia α1 Adrenergic Agonist Market Size (2014-2019)
• 9.2 α1 Adrenergic Agonist Key Players in Southeast Asia
• 9.3 Southeast Asia α1 Adrenergic Agonist Market Size by Type
• 9.4 Southeast Asia α1 Adrenergic Agonist Market Size by Application

10 India

• 10.1 India α1 Adrenergic Agonist Market Size (2014-2019)
• 10.2 α1 Adrenergic Agonist Key Players in India
• 10.3 India α1 Adrenergic Agonist Market Size by Type
• 10.4 India α1 Adrenergic Agonist Market Size by Application

11 Central & South America

• 11.1 Central & South America α1 Adrenergic Agonist Market Size (2014-2019)
• 11.2 α1 Adrenergic Agonist Key Players in Central & South America
• 11.3 Central & South America α1 Adrenergic Agonist Market Size by Type
• 11.4 Central & South America α1 Adrenergic Agonist Market Size by Application

12 International Players Profiles

• 12.1 Bausch Health Companies
  • 12.1.1 Bausch Health Companies Company Details
  • 12.1.2 Company Description and Business Overview
  • 12.1.3 α1 Adrenergic Agonist Introduction
  • 12.1.4 Bausch Health Companies Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.1.5 Bausch Health Companies Recent Development
• 12.2 Pfizer
  • 12.2.1 Pfizer Company Details
  • 12.2.2 Company Description and Business Overview
  • 12.2.3 α1 Adrenergic Agonist Introduction
  • 12.2.4 Pfizer Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.2.5 Pfizer Recent Development
• 12.3 Sterling Winthrop
  • 12.3.1 Sterling Winthrop Company Details
  • 12.3.2 Company Description and Business Overview
  • 12.3.3 α1 Adrenergic Agonist Introduction
  • 12.3.4 Sterling Winthrop Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.3.5 Sterling Winthrop Recent Development
• 12.4 Sanofi
  • 12.4.1 Sanofi Company Details
  • 12.4.2 Company Description and Business Overview
  • 12.4.3 α1 Adrenergic Agonist Introduction
  • 12.4.4 Sanofi Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.4.5 Sanofi Recent Development
• 12.5 Paragon BioTeck
  • 12.5.1 Paragon BioTeck Company Details
  • 12.5.2 Company Description and Business Overview
  • 12.5.3 α1 Adrenergic Agonist Introduction
  • 12.5.4 Paragon BioTeck Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.5.5 Paragon BioTeck Recent Development
• 12.6 West-Ward Pharmaceuticals
  • 12.6.1 West-Ward Pharmaceuticals Company Details
  • 12.6.2 Company Description and Business Overview
  • 12.6.3 α1 Adrenergic Agonist Introduction
  • 12.6.4 West-Ward Pharmaceuticals Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.6.5 West-Ward Pharmaceuticals Recent Development
• 12.7 Biosyent Pharma
  • 12.7.1 Biosyent Pharma Company Details
  • 12.7.2 Company Description and Business Overview
  • 12.7.3 α1 Adrenergic Agonist Introduction
  • 12.7.4 Biosyent Pharma Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.7.5 Biosyent Pharma Recent Development
• 12.8 Novartis
  • 12.8.1 Novartis Company Details
  • 12.8.2 Company Description and Business Overview
  • 12.8.3 α1 Adrenergic Agonist Introduction
  • 12.8.4 Novartis Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.8.5 Novartis Recent Development
• 12.9 Omega Laboratories
  • 12.9.1 Omega Laboratories Company Details
  • 12.9.2 Company Description and Business Overview
  • 12.9.3 α1 Adrenergic Agonist Introduction
  • 12.9.4 Omega Laboratories Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.9.5 Omega Laboratories Recent Development
• 12.10 Medical Purchasing Solutions
  • 12.10.1 Medical Purchasing Solutions Company Details
  • 12.10.2 Company Description and Business Overview
  • 12.10.3 α1 Adrenergic Agonist Introduction
  • 12.10.4 Medical Purchasing Solutions Revenue in α1 Adrenergic Agonist Business (2014-2019)
  • 12.10.5 Medical Purchasing Solutions Recent Development
• 12.11 Avadel Legacy Pharmaceuticals
• 12.12 Amneal Biosciences
• 12.13 Cipla USA
• 12.14 Par Pharmaceutical
• 12.15 Glaxosmithkline
• 12.16 Teva
• 12.17 Bayer
• 12.18 Impax Generics
• 12.19 Mylan Pharmaceuticals
• 12.20 Physicians Total Care
• 12.21 Merck

13 Market Forecast 2019-2025

• 13.1 Market Size Forecast by Regions
• 13.2 United States
• 13.3 Europe
• 13.4 China
• 13.5 Japan
• 13.6 Southeast Asia
• 13.7 India
• 13.8 Central & South America
• 13.9 Market Size Forecast by Product (2019-2025)
• 13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 12.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Disclaimer